Literature DB >> 10347091

EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature.

R C Kowal1, J A Richardson, J M Miano, E N Olson.   

Abstract

A hallmark of vascular lesions is the phenotypic modulation of vascular smooth muscle cells (VSMCs) from a quiescent, contractile state to a more primitive, proliferative phenotype with a more fetal pattern of gene expression. Using subtraction hybridization to identify genes that may regulate this transition, we cloned a novel gene named EVEC, an acronym for its expression in the embryonic vasculature and the presence of Ca2+ binding epidermal growth factor-like repeats contained in the predicted protein structure. Although these repeats are characteristic of the extracellular matrix proteins, fibrillin, fibulin, and the latent transforming growth factor-beta binding proteins, EVEC most closely resembles the H411 and T16/S1-5 gene products, the latter of which are believed to regulate DNA synthesis in quiescent fibroblasts. Using in situ hybridization, we demonstrated that EVEC is expressed predominantly in the VSMCs of developing arteries in E11.5 through E16.5 mouse embryos. Lower levels of expression are also observed in endothelial cells, perichondrium, intestine, and mesenchyme of the face and kidney. EVEC mRNA expression is dramatically downregulated in adult arteries, except in the uterus, where cyclic angiogenesis continues; however, EVEC expression is reactivated in 2 independent rodent models of vascular injury. EVEC mRNA is observed in cellular elements of atherosclerotic plaques of LDL receptor-deficient, human apolipoprotein B transgenic mice and in VSMCs of the media and neointima of balloon-injured rat carotid arteries. These data suggest that EVEC may play an important role in the regulation of vascular growth and maturation during development and in lesions of injured vessels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347091     DOI: 10.1161/01.res.84.10.1166

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  38 in total

Review 1.  Fibulins: physiological and disease perspectives.

Authors:  W Scott Argraves; Lisa M Greene; Marion A Cooley; William M Gallagher
Journal:  EMBO Rep       Date:  2003-12       Impact factor: 8.807

2.  Biomechanical and microstructural properties of common carotid arteries from fibulin-5 null mice.

Authors:  William Wan; Hiromi Yanagisawa; Rudolph L Gleason
Journal:  Ann Biomed Eng       Date:  2010-07-08       Impact factor: 3.934

3.  Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells.

Authors:  M Preis; J Schneiderman; B Koren; Y Ben-Yosef; D Levin-Ashkenazi; S Shapiro; T Cohen; M Blich; M Israeli-Amit; Y Sarnatzki; D Gershtein; R Shofti; B S Lewis; Y Shaul; M Y Flugelman
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

4.  Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Authors:  Alexander Kapustin; Victoria Stepanova; Natalia Aniol; Douglas B Cines; Alexei Poliakov; Serge Yarovoi; Tatiana Lebedeva; Robin Wait; Grigory Ryzhakov; Yelena Parfyonova; Yaroslav Gursky; Hiromi Yanagisawa; Mikhail Minashkin; Robert Beabealashvilli; Alexander Vorotnikov; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2012-04-15       Impact factor: 3.857

5.  Altered vascular remodeling in fibulin-5-deficient mice reveals a role of fibulin-5 in smooth muscle cell proliferation and migration.

Authors:  Jeffrey A Spencer; Shelby L Hacker; Elaine C Davis; Robert P Mecham; Russ H Knutsen; Dean Y Li; Robert D Gerard; James A Richardson; Eric N Olson; Hiromi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

6.  Expression, purification, and characterization of recombinant fibulin-5 in a prokaryote expression system.

Authors:  Myoung Seok Jeong; Chang Soo Kang; Yeon Soo Han; In Seok Bang
Journal:  J Microbiol       Date:  2010-11-03       Impact factor: 3.422

Review 7.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

8.  Differential expression of fibulin family proteins in the para-cervical weak zone and other areas of human fetal membranes.

Authors:  R M Moore; R W Redline; D Kumar; B M Mercer; J M Mansour; E Yohannes; J B Novak; M R Chance; J J Moore
Journal:  Placenta       Date:  2009-02-23       Impact factor: 3.481

9.  Structural effects of fibulin 5 missense mutations associated with age-related macular degeneration and cutis laxa.

Authors:  Richard P O Jones; Caroline Ridley; Thomas A Jowitt; Ming-Chuan Wang; Marjorie Howard; Nicoletta Bobola; Tao Wang; Paul N Bishop; Cay M Kielty; Clair Baldock; Andrew J Lotery; Dorothy Trump
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

10.  Fibulin-5 expression is decreased in women with anterior vaginal wall prolapse.

Authors:  Peter Takacs; Mehdi Nassiri; Anita Viciana; Keith Candiotti; Alessia Fornoni; Carlos A Medina
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.